Skip to content

Interactive exercise therapy at home: a web based solution to improve long-term adherence, self-management and clinical efficacy of a life-style intervention program for patients with Type 2 Diabetes

Interactive exercise therapy at home: a web based solution to improve long-term adherence, self-management and clinical efficacy of a life-style intervention program for patients with Type 2 Diabetes - Web based interactive exercise therapy for Type 2 Diabetes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39505
Enrollment
72
Registered
2010-02-01
Start date
2010-04-28
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult onset diabetes Diabetes type 2

Interventions

Patients will be randomized to follow either a supervised progressive interval endurance and resistance type of training at the ErasmusMC (13 weeks) combined with an interactive web based (LiveWorko

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Type 2 diabetes 3 maanden-15 years - Age: 35-75 yrs - Access to broadband internet including a personal computer with minimally WindowsXP/MacOSX and a USB-connection

Exclusion criteria

Exclusion criteria: - Cardio-vascular disease - Severe orthopaedic impairments - Renal failure or >grade III retinopathy - Previous diabetic foot ulcer that limits exercise training - Cerebro-vascular disease (CVA), neurological diseases or deficits

Design outcomes

Primary

MeasureTime frame
Adherence to the exercise program as measured by percentage of dropouts as well as an increase in total weekly energy expenditure. The feasibility of the LiveWorkout and Live Workout program.

Secondary

MeasureTime frame
Movement-related everyday activity/energy expenditure and functional capacity Muscle strength and resistance to fatigue Glycemic control (HbA1c) and fasting plasma glucose Cardiovascular risk profile

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)